Search

Your search keyword '"Jarahian M"' showing total 42 results

Search Constraints

Start Over You searched for: Author "Jarahian M" Remove constraint Author: "Jarahian M"
42 results on '"Jarahian M"'

Search Results

2. Activation of AMP-activated protein kinase sensitizes lung cancer cells and H1299 xenografts to erlotinib

3. The AP-1 transcription factor JunB is essential for multiple myeloma cell proliferation and drug resistance in the bone marrow microenvironment

4. The AP-1 Transcription Factor JunB Promotes Multiple Myeloma (MM) Cell Proliferation, Survival and Drug Resistance in the Bone Marrow Microenvironment

5. The AP-1 transcription factor JunB is essential for multiple myeloma cell proliferation and drug resistance in the bone marrow microenvironment

8. Nicaraven-loaded electrospun wound dressings promote diabetic wound healing via proangiogenic and immunomodulatory functions: a preclinical investigation.

9. Dysregulation of Survivin-Targeting microRNAs in Autoimmune Diseases: New Perspectives for Novel Therapies.

10. Activating Natural Killer Cell Receptors, Selectins, and Inhibitory Siglecs Recognize Ebolavirus Glycoprotein.

11. The Role of Janus Kinase/STAT3 Pathway in Hematologic Malignancies With an Emphasis on Epigenetics.

12. MicroRNAs and JAK/STAT3 signaling: A new promising therapeutic axis in blood cancers.

13. Cloning and Embryo Splitting in Mammalians: Brief History, Methods, and Achievements.

14. Optimizing sgRNA to Improve CRISPR/Cas9 Knockout Efficiency: Special Focus on Human and Animal Cell.

15. Re-Expression of Poly/Oligo-Sialylated Adhesion Molecules on the Surface of Tumor Cells Disrupts Their Interaction with Immune-Effector Cells and Contributes to Pathophysiological Immune Escape.

16. Liposomes: Structure, Biomedical Applications, and Stability Parameters With Emphasis on Cholesterol.

17. CAR-NK cell in cancer immunotherapy; A promising frontier.

18. Mesenchymal Stem/Stromal Cells as a Vehicle for Cytokine Delivery: An Emerging Approach for Tumor Immunotherapy.

19. Novel CAR T therapy is a ray of hope in the treatment of seriously ill AML patients.

20. Harnessing TRAIL-Induced Apoptosis Pathway for Cancer Immunotherapy and Associated Challenges.

22. The lethal internal face of the coronaviruses: Kidney tropism of the SARS, MERS, and COVID19 viruses.

23. A paradigm shift in cell-free approach: the emerging role of MSCs-derived exosomes in regenerative medicine.

24. Mesenchymal Stem/Stromal Cell-Based Delivery: A Rapidly Evolving Strategy for Cancer Therapy.

25. Up-regulation of KISS1 as a novel target of Let-7i in melanoma serves as a potential suppressor of migration and proliferation in vitro.

26. Bi/tri-specific antibodies (HN-Fc-CD16 and HN-Fc-IL-15-CD16) cross-linking natural killer (NK)-CD16 and Newcastle Disease Virus (NDV)-HN, enhanced NK activation for cancer immunotherapy.

27. A Deep Insight Into CAR-T Cell Therapy in Non-Hodgkin Lymphoma: Application, Opportunities, and Future Directions.

28. CAR-NK Cell: A New Paradigm in Tumor Immunotherapy.

29. Mesenchymal stem/stromal cell-derived exosomes in regenerative medicine and cancer; overview of development, challenges, and opportunities.

30. Any closer to successful therapy of multiple myeloma? CAR-T cell is a good reason for optimism.

31. Renaissance of armored immune effector cells, CAR-NK cells, brings the higher hope for successful cancer therapy.

32. Mesenchymal stem/stromal cells as a valuable source for the treatment of immune-mediated disorders.

33. CAR T cells in solid tumors: challenges and opportunities.

34. The CCR5 antagonist maraviroc causes remission of pancreatic cancer liver metastasis in nude rats based on cell cycle inhibition and apoptosis induction.

35. Expression and Purification of a Bispecific Antibody against CD16 and Hemagglutinin Neuraminidase (HN) in E. Coli for Cancer Immunotherapy.

36. Brain tumour cells interconnect to a functional and resistant network.

37. Activation of AMP-activated protein kinase sensitizes lung cancer cells and H1299 xenografts to erlotinib.

38. Modulation of NKp30- and NKp46-mediated natural killer cell responses by poxviral hemagglutinin.

39. Activation of natural killer cells by newcastle disease virus hemagglutinin-neuraminidase.

40. Altered glycosylation of recombinant NKp30 hampers binding to heparan sulfate: a lesson for the use of recombinant immunoreceptors as an immunological tool.

41. Expression analysis of the ligands for the Natural Killer cell receptors NKp30 and NKp44.

42. Blockade of natural killer cell-mediated lysis by NCAM140 expressed on tumor cells.

Catalog

Books, media, physical & digital resources